首页> 外文期刊>Vaccine >Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults
【24h】

Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults

机译:降低抗原含量的白喉-破伤风-无细胞百日咳组合疫苗和小儿麻痹症疫苗(dTpa-IPV),用于成人加强免疫

获取原文
获取原文并翻译 | 示例
           

摘要

Many countries recommend diphtheria, tetanus and/or poliomyelitis boosters in adolescents or adults and the need for pertussis booster vaccination beyond childhood is increasingly recognized. A new combined reduced-antigen-content dTpa-IPV vaccine provides booster vaccination against all four diseases in one single injection. The immunogenicity and safety of the dTpa-IPV vaccine was compared to that of licensed dTpa+IPV or Td-IPV vaccines in 806 adolescents >14 years of age and adults with a heterogeneous vaccination history. The dTpa-IPV vaccine was immunogenic and well tolerated. No clinically significant differences were observed between groups. Anti-tetanus antibody kinetics indicated that each of the vaccines could be used for tetanus prophylaxis in acute wound management. For all vaccines, the lowest post-vaccination antibody concentrations were observed in subjects >40 years of age, those seronegative prior to vaccination and those subjects whose last vaccination was > or =20 years ago. In conclusion, dTpa-IPV vaccination of subjects over 14 years of age was as immunogenic and well tolerated as the licensed dTpa+IPV or Td-IPV vaccines. Vaccination coverage of adults is poor and the use of combined vaccines such as dTpa-IPV during vaccination visits, or for wound management, maximizes opportunities for boosting in these difficult to reach age groups.
机译:许多国家建议在青少年或成人中使用白喉,破伤风和/或小儿麻痹症加强免疫药,并且越来越多地认识到儿童期以后需要百日咳加强免疫疫苗。一种新的降低抗原含量的组合dTpa-IPV疫苗可通过一次注射对所有四种疾病进行加强免疫。将dTpa-IPV疫苗的免疫原性和安全性与许可的dTpa + IPV或Td-IPV疫苗的免疫原性和安全性进行了比较,在806名14岁以上的青少年中以及有不同疫苗接种历史的成年人中。 dTpa-IPV疫苗具有免疫原性和良好的耐受性。两组之间没有观察到临床上的显着差异。抗破伤风抗体的动力学表明,每种疫苗均可用于急性伤口处理中的破伤风预防。对于所有疫苗,在> 40岁的受试者,那些在疫苗接种之前呈血清阴性的受试者以及最近一次疫苗接种≥20年的受试者中,观察到了最低的疫苗接种后抗体浓度。总之,对14岁以上的受试者进行dTpa-IPV疫苗的免疫原性和耐受性与许可的dTpa + IPV或Td-IPV疫苗相同。成人的疫苗接种覆盖率很差,在疫苗访视期间或伤口处理中使用诸如dTpa-IPV的联合疫苗,可以最大程度地增加这些难以达到的年龄组的疫苗接种机会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号